Celldex Therapeutics (CLDX) gains on strong drug test results
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares gained 3.3% to $9.20. The company, on Feb. 14, presented final results from a Phase 1 study of CDX-301 (recombinant human Flt3L; rhuFlt3L) in healthy volunteers that strongly support the initiation of a pilot study in hematopoietic stem cell transplantation later this year. Share volume was 1.6 million, compared to an all-day average of 1.2 million
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here